Thursday 16 October, 2025
Introduction: Pegylated derivatives of recombinant human erythropoietin EPOrh provides therapeutic alternatives with longer half-life and thus longer treatment duration for the…
Read moreAbstracts
Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects
Thursday 16 October, 2025
Objectives: More antibody drugs are being made in di- and trimer forms to bind multiple targets in a pathway or…
Read moreOptimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment
Thursday 16 October, 2025
Objectives: The emergence of anti-programmed cell death ligand 1 (PD-L1) inhibitors marks a sophisticated approach in cancer therapeutics, strategically addressing…
Read moreMaS: population pharmacometric modeling in Python
Thursday 16 October, 2025
Introduction: MaS [1] is a software package for modeling and simulation in pharmacometrics and statistics. Its modeling language is built…
Read moreQuantifying the impact of infection on murine antibiotic exposure in the framework of non-conventional treatment modalities within the FAIR study
Thursday 16 October, 2025
Introduction: Antibiotic resistance has been declared “one of the biggest threats to global health, food security, and development today” by…
Read moreEnalapril orodispersible minitablets for pediatric heart failure – a population pharmacokinetic analysis from multicenter Phase II/III LENA clinical trials
Thursday 16 October, 2025
Introduction: Enalapril is an angiotensin-converting enzyme inhibitor (ACEI) and is widely used in the treatment of pediatric heart failure without an…
Read morePharmacokinetic model-informed precision dosing of natalizumab in Multiple Sclerosis
Thursday 16 October, 2025
Introduction: Natalizumab is highly effective in treating relapsing-remitting multiple sclerosis. However, the standard intravenous treatment interval of 4 weeks may…
Read moreDo critically ill patients undergoing continuous renal replacement therapy require ceftaroline dosage adjustments? Ceftaroline PopPK model and dosage simulations with probability of target attainment analysis based on retrospective data.
Thursday 16 October, 2025
Introduction/Objectives: Ceftaroline is a fifth-generation cephalosporin reserved for treating resistant gram-positive and gram-negative bacteria [1]. Currently, no dosing standards have…
Read moreAntibiotic pharmacokinetic modelling versus antibiotic therapy optimisation and resistance reduction: Bibliometric analysis
Thursday 16 October, 2025
Objectives: Modern statistics and pharmacokinetic (PK) modelling are increasingly applied to calculate personalised dosage regimens or estimate unique drug dosage…
Read moreA minimal PBPK model to unveil anti-tuberculosis drug distribution in pulmonary lesions: a blueprint for improving efficacy screenings.
Thursday 16 October, 2025
Objectives: With a human toll of 1.6 million lives in 2021, tuberculosis (TB) is among the most aggressive infectious diseases worldwide,…
Read more